The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- NJACTS Community Engagement Core Available Services
- Professor’s Research into Human Genetics Points to New Ways of Treating a Painful Gastrointestinal Disease.
- Modernizing Health Records for the Most Vulnerable.
- For Rutgers Health’s First Chancellor, Mentoring Was the Mission.
- Inspired by a Family’s Struggle, a Scientist Helps Uncover Defense Against Alzheimer’s Disease.
Categories
- Community (2,419)
- Covid (994)
- CTO Events (6)
- News (3,061)
- Pilots (21)